Comparative Pharmacology
Head-to-head clinical analysis: DROSPIRENONE AND ETHINYL ESTRADIOL versus STILBESTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DROSPIRENONE AND ETHINYL ESTRADIOL versus STILBESTROL.
DROSPIRENONE AND ETHINYL ESTRADIOL vs STILBESTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Drospirenone is a spironolactone analogue with anti-mineralocorticoid and anti-androgenic activity. It suppresses gonadotropin secretion, inhibiting ovulation. Ethinyl estradiol provides negative feedback on LH and FSH, preventing follicular development and ovulation.
Synthetic nonsteroidal estrogen that acts by binding to estrogen receptors (ERα and ERβ), leading to translocation to the nucleus, modulation of gene transcription, and promotion of estrogenic effects in target tissues.
One tablet (drospirenone 3 mg/ethinyl estradiol 0.02 mg or 0.03 mg) orally once daily for 21 days followed by 7 days of placebo, or 24 active tablets followed by 4 placebo tablets depending on formulation.
0.5 to 2 mg orally once daily; or 25 mg intramuscularly once daily for 5 days; for prostate cancer: 1 to 3 mg orally once daily.
None Documented
None Documented
Clinical Note
moderateDiethylstilbestrol + Digoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDiethylstilbestrol + Digitoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDiethylstilbestrol + Deslanoside
"Diethylstilbestrol may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDiethylstilbestrol + Acetyldigitoxin
Drospirenone: approximately 30-35 hours (terminal), allowing once-daily dosing. Ethinyl estradiol: approximately 13-20 hours (terminal), supporting daily administration.
Terminal elimination half-life is approximately 24-48 hours, with a prolonged phase due to enterohepatic recirculation; requires dosing adjustment in hepatic impairment.
Drospirenone: ~40-50% renal (as glucuronide conjugates), ~50-60% fecal. Ethinyl estradiol: ~40% renal, ~60% fecal, primarily as glucuronide and sulfate conjugates.
Renal excretion of glucuronide and sulfate conjugates accounts for approximately 60-80% of an administered dose; biliary/fecal excretion accounts for 15-30%; less than 5% is excreted unchanged in urine.
Category D/X
Category C
Estrogen
Estrogen
"Diethylstilbestrol may decrease the cardiotoxic activities of Acetyldigitoxin."